医学
内科学
突变
癌症
克拉斯
肺癌
癌症研究
遗传学
生物
基因
作者
Pasi A. Jänne,Gregory J. Riely,Shirish M. Gadgeel,Rebecca S. Heist,Sai‐Hong Ignatius Ou,Jose M. Pacheco,Melissa L. Johnson,Joshua K. Sabari,Konstantinos Leventakos,Edwin Yau,Lyudmila Bazhenova,Marcelo V. Negrão,Nathan A. Pennell,Jun Zhang,Kenna Anderes,Hirak Der‐Torossian,Thian Kheoh,Karen Velastegui,Xiaohong Yan,James G. Christensen
标识
DOI:10.1056/nejmoa2204619
摘要
In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
科研通智能强力驱动
Strongly Powered by AbleSci AI